AbbVie Inc.
Researches, develops, manufactures and sells biopharmaceutical medicines and therapies worldwide, best known for treatments across immunology, oncology, gastroenterology, neurology, ophthalmology and aesthetics.
As of Jul 17, 2026
Executive summary
AbbVie Inc. is a healthcare company trading on the NYSE at $254.39 per share. The stock shows a neutral technical bias despite strong recent performance, having gained 15.6% over one month and 40.7% over the past year. With a market capitalisation of $449 billion, AbbVie continues to rank among the largest healthcare businesses by value.
Price history
As of Jul 16, 2026
Performance
+4.21%
+2.52%
+15.62%
+22.93%
+13.97%
+40.72%
As of Jul 16, 2026
Technical indicators
- 65.8
- -1.02Bearish
- 50: 225.61 · 200: 219.76Bullish
- $213.85 / $259.79
Technical Bias
AbbVie's technical indicators are split: moving averages favour higher prices, whilst MACD signals weakening momentum, and RSI sits neutral in the middle ground. This even three-way tally produces a neutral technical read, not a buy or sell signal.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 16, 2026
Fundamentals
- $449B
- 118.87
- $2.14
- 5.79%
- +12.4%
- $17.8B
- 0.28
- $179.07 – $259.79
- 2.83%
- Jul 15, 2026
- Jul 31, 2026 (13 days)
As of Jul 17, 2026
Upcoming catalysts
- Earnings report
As of Jul 17, 2026
Latest news
As of Jul 17, 2026
Short-term outlook
Over the next few weeks, AbbVie's picture stays mixed: RSI at 65.8 is neutral but leaning warm after a strong 15.6% one-month run, while MACD points bearish even as price holds above both the 50-day (225.61) and 200-day (219.76) averages. With no earnings until July 2026, watch $259.79 as the level to clear and $213.85 as the support to hold.
Medium-term outlook
Over the next few quarters, AbbVie's outlook hinges on whether its 12.4% revenue growth can translate into stronger profitability, given a currently modest 5.8% profit margin and a rich 118.87 P/E that leaves little room for disappointment. The 2.8% dividend yield offers some income support, while the neutral technical bias suggests the stock isn't showing a clear directional lean at present.
Key risks
- The stock trades at a very high price-to-earnings ratio of 118.87, meaning expectations are elevated and any disappointment could hit the shares hard.
- Profit margin sits at a thin 5.8%, leaving little cushion if costs rise or pricing pressure increases.
- AbbVie's growing aesthetics business, including new approvals like Boey in Europe, faces a crowded and competitive field where new entrants could limit uptake.
- Trading near the top of its 52-week range at $254.39, close to the $259.79 high, the stock has less room for error priced in versus its $179.07 low.
About AbbVie Inc.
AbbVie Inc. (NYSE: ABBV) is a major US drug manufacturer operating in the broader healthcare sector. With a market capitalisation of $449 billion, it ranks among the largest pharmaceutical companies listed on the exchange, reflecting its scale and established position within the general drug manufacturing industry.
Looking at AbbVie's key figures, the price-to-earnings ratio of 118.87 stands out as notably high, suggesting the market is pricing in expectations well beyond current earnings, or that recent earnings have been unusually low relative to the share price. Alongside this, the dividend yield of +2.8% shows AbbVie continues to return cash to shareholders. Together, these figures give investors a snapshot of how the market currently values the company relative to its earnings and income distribution.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.